Union City, CA, United States of America

Diane Feingersh



Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 67(Granted Patents)


Location History:

  • Hayward, CA (US) (2010)
  • Union City, CA (US) (2007 - 2012)

Company Filing History:


Years Active: 2007-2012

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Diane Feingersh: Innovator in Cancer Treatment

Introduction

Diane Feingersh is a prominent inventor based in Union City, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies for cancer treatment. With a total of 5 patents to her name, her work has the potential to impact the lives of many patients.

Latest Patents

One of her latest patents is focused on neutralizing human anti-IGFR antibodies. This invention includes fully human, neutralizing, monoclonal antibodies against the human Insulin-like Growth Factor Receptor-I (IGFR1). These antibodies are designed to be useful for treating or preventing cancer in a subject. Additionally, the patent outlines methods for using and producing these antibodies, showcasing her innovative approach to cancer therapy.

Career Highlights

Throughout her career, Diane has worked with notable companies such as Schering Corporation and Merck Sharp & Dohme Corporation. Her experience in these organizations has allowed her to refine her skills and contribute to groundbreaking research in the field of oncology.

Collaborations

Diane has collaborated with esteemed colleagues, including Yan Wang and Robert Greenberg. These partnerships have further enhanced her research and development efforts, leading to advancements in cancer treatment.

Conclusion

Diane Feingersh is a trailblazer in the field of biotechnology, with her innovative patents paving the way for new cancer therapies. Her dedication to research and collaboration with industry leaders exemplifies her commitment to improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…